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The presentation of Hodgkin Lymphoma in a thymic cyst is rare. We describe a case in a 9 year-old boy, with a long follow-up
course, complicated by two secondary neoplasms and a post bone marrow transplant lymphoproliferative disorder. We also review
the literature on such presentations and second malignant neoplasms in childhood.
1.Introduction
Mediastinal disease in the context of Hodgkin lymphoma is
a frequent ﬁnding. However, the association of a Hodgkin
lymphoma with a thymic cyst is rarely reported [1]. Here,
we describe a case in a 9-year-old boy, with a long follow-up
course, complicated by two secondary neoplasms and a post
bone marrow transplant lymphoproliferative disorder.
2.CaseReport
A 9-year-old boy presented in 1993 with a one-week history
of cough and fever. He had a WBC 16000K/cumm, Hgb
12.7g/dL. Chest X-ray (CXR) revealed a consolidated right
middle lobe. Suspecting pneumonia, he received a course
of antibiotics. His symptoms improved slightly but his CXR
remained unchanged after the course of antibiotics. CT scan
demonstrated mediastinal lymphadenopathy and a 13cm
anterior mediastinal mass (Figure 1). A needle aspirate of
the intralesional ﬂuid demonstrated a ﬁbrinous exudate
with benign mononuclear cells and epithelial lining cells
consistent with a thymic cyst contents. Biopsy of the mass
showed a mixed inﬂammatory cell inﬁltrate with atypical
largemononuclearcellsconsistentwithReed-Sternbergcells.
The neoplastic cells were present in nodules separated by
d e n s eﬁ b r o u ss e p t a e( Figure 2). They showed positivity for
CD15 with negative CD45 by immunoperoxidase method.
CD30 was positive in the cytoplasm of Reed-Sternberg
cells with perinuclear accentuation in some of the cells. A
diagnosis of Hodgkin lymphoma, nodular sclerosis arising in
conjunction with a thymic cyst, was rendered. Pleural ﬂuid
was positive for Hodgkin lymphoma, and a bone marrow
biopsy showed no evidence of lymphoma.
ThepatientwasstagedatIIAEandstartedonchemother-
apy with the following regimen: Nitrogen mustard, Pred-
nisone, Vincristine, and Procarbazine (MOPP). He received
six cycles of chemotherapy. Chest and mediastinal radio-
therapy was initiated given his bulky disease. He received
2340cGy to an AP/PA mantle ﬁeld in 13 fractions with 6MV
photons.
At the age of 18 years (in the year 2002) he developed
a left scapular pain and was clinically presumed to be
caused by bursitis. Having the pain persisted for four
months, an MRI was ordered disclosing a 10cm soft tissue
mass surrounding the left scapula, which had multiple
calciﬁcations and had eroded into the scapula. Chest X-ray
showed a single small nodule within the right lower lobe
of the lung. Biopsy of the periscapular mass demonstrated
a chondroblastic osteosarcoma (Figure 3). The osteosarcoma
was present within the ﬁeld of radiation therapy directed to2 Case Reports in Medicine
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Figure 1: CTscan demonstratingalarge cystic anterior mediastinal
mass (arrow).
the chest and mediastinum that had been given following
his diagnosis of Hodgkin lymphoma ten years prior to his
current presentation. He received Cisplatin, Doxorubicin,
and Methotrexate. Subsequently, he had an amputation of
the left shoulder and resection of the lung nodule.
At the age of 22 (in 2006) he presented with fever, cough,
night sweats, fatigue, decreased appetite, and a weight loss of
25 pounds. A peripheral blood count showed white blood
cells: 6.8K/cumm, red blood cells: 2.78M/cumm, Hgb:
9.5g/dL, and platelet: 172,000K/cumm. Peripheral blood
diﬀerential count showed: 3% myelocytes, 2% metamyelo-
cytes, 22% bands, 9% segmented neutrophils, 24% lympho-
cytes, 38% monocytes, and 2% eosinophils.
A bone marrow aspirate smear showed increased cellular
elements with blasts, constituting 82% of marrow cells.
These blasts were medium-to-large sized with scanty-to-
moderate cytoplasm, mostly ﬁne red cytoplasmic granules,
round to lobulated or bean-shaped nuclei, and variably
conspicuous nucleoli (Figure 4). No Auer rods were encoun-
tered. Myeloid, erythroid cells, and megakaryocytes were
markedly decreased. A diﬀerential count on bone marrow
aspirate smear showed the following: 10% myeloid cells,
1% erythroid cells, 5% lymphocytes, 2% monocytes, and
82% myeloblasts. Immunophenotyping by ﬂow cytometry
showed blasts positivity for CD13, CD33, and myeloperox-
idase, CD11b, CD11c, and HLA: DR. A bone marrow biopsy
showed an increased cellularity (95%) with replacement
of architecture by sheets of myeloblasts. The diagnosis of
Secondary AML was made.
The patient was put on an acute myelogenous leukemia
protocol and underwent bone marrow transplantation after-
wards. His course was complicated by an EBV-associated
lymphoproliferative disease and graft-versus-host disease.
His status deteriorated and he developed fever of unknown
origin with an altered mental status and tachypnea and he
passed away within days of onset of the fever at the age of 23
years.
3. Discussion
Mediastinal enlargement in patients with Hodgkin lym-
phoma (HL) can be attributable to mediastinal lym-
phadenopathy, thymic involvement by HL, or rarely the
presence of thymic cysts [1]. In 1983, Smith et al. reported
a case whereby the initial presentation in a 14-year-old boy
w a st h a to fal a r g et h y m i cc y s tw i t ham i c r o s c o p i cf o c u so f
Hodgkin lymphoma discovered in the wall of the cyst [2].
Our case had a similar presentation.
In 1987, a review of literature reported 11 cases ranging
in age between 17 and 40 years. In this series, 60% of the
cases were of nodular sclerosis subtype and 40% were of
mixed cellularity subtype [1]. There is no documented sex
predilection.
The pathogenesis of cyst formation in the thymus in
conjunction of HL is unclear. Possible explanations include
a secondary treatment eﬀect or thymic tissue inﬁltration by
neoplastic cells [3].
Thymic cysts can be microscopic or macroscopic and can
reach sizes of 9–12cm. They contain clear straw color or
hemorrhagic ﬂuid. Microscopically, thymic cysts are lined
by thymic epithelial cells with intervening thymic tissue
[4]. In cases where there is concurrent lymphoma within
the thymus, the classic histology of the Hodgkin subtype is
noted.
The presence of a thymic cyst in patients with Hodgkin
lymphoma does not necessitate any speciﬁc additional
treatment. However, awareness of this association is of
importanceinraisingthediﬀerentialofacoexistingHodgkin
lymphoma in patients who present with thymic cysts. It
also carries implications of posttreatment residual disease.
The persistence of the thymic cysts after treatment can
confound a completely resolved HL and give the impres-
sion of a residual disease [4]. Some authors advocate
follow-up of these cysts without any diagnostic or ther-
apeutic intervention based on their experience with no
progression of these cysts after 2–6 years of follow-up,
although, others suggest that biopsy conﬁrmation of HL
is needed before treating such residual thymic cysts [3].
With the increased cure rate in patients with Hodgkin
Lymphoma, the risk of secondary malignancy is increased.
The relative rate of developing a secondary malignancy
i nH Ls u r v i v o r si s2 . 2 2 %[ 5]. Earlier reports implicated
leukemia as the most common secondary malignancy in
patients with HL. Recent data showed that 76% of sec-
ondary malignancies in HL survivors are solid tumors
which may appear in the areas of the lung, breast,
bone, thyroid, and soft tissue sarcomas [5]. They occur
after a minimal latency of 5–10 years. A number of
etiological factors have been suggested and include can-
cer therapy (chemotherapy and radiotherapy), underlying
cancer predisposing syndromes (e.g., Bloom syndrome),
or other modiﬁable factors (smoking, alcohol, and diet)
[5].
The majority of secondary AML (sAML) occurs in the
ﬁrst year after treatment of the primary malignancy [6].
The risk of developing secondary AML is associated with a
numberoffactorsincludingtypeofchemotherapeuticagents
used, radiotherapy, and some host genetic factors. sAML
associated with alkylating agents occurs 5–7 years following
therapy and has been shown to be dose-related [7]. Most
of these cases are of M1 or M2 subtype. On the other
hand, sAML occurring in patients receiving topoisomerase
II inhibitors is dose-independent and of myelomonocyticCase Reports in Medicine 3
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Figure 2: Hodgkin lymphoma in thymic cyst. (a) Wall of thymic cyst with nodules of cellular/inﬂammatory inﬁltrates (H&E. 25×).
(b) Thymic cyst wall devoid of epithelium demonstrating the mixed inﬂammatory inﬁltrate in wall (H&E. 100×). (c) Hassel corpuscles
surrounded by classic Reed-Sternberg cells in a mixed inﬂammatory background (H&E. 200×). (d) Classic Reed Sternberg cells present in a
mixed inﬂammatory background of lymphocytes, histiocytes, and eosinophils (H&E. 400×).
(a) (b)
Figure 3: Osteosarcoma: (a) gross photograph of resected specimen demonstrating a large lesion in scapula extending into soft tissue.
(b) Representative microscopic section showing pleomorphic and spindle cells with hyperchromatic nuclei and osteoid production. (H&E.
200×).4 Case Reports in Medicine
Figure 4: Bone marrow aspirate smear showing medium-to-large
sized myeloblasts with moderate cytoplasm, round to lobulated
or bean-shaped nuclei, and variably conspicuous nucleoli. (H&E.
400×).
subtype. Prognosis in cases of s-AML is worse than patients
with primary AML [7].
In a review of cancer registries in a number of countries
from 1970 to 2001, Schonfeld et al. noted that the incidence
of acute myelogenous leukemia in patient with HL has
declined. They propose that this change is probably related
to change in chemotherapy [8]. Earlier chemotherapeutic
regimens for the treatment of HL used MOPP which
had a great eﬃcacy in combating the disease but was
associated with toxicity and long-term risk of developing
acute leukemia or myelodysplastic syndromes. More recent
modalities utilize ABVDwhichhasalowerrisk of developing
hematopoietic malignancies [9].
The National institute of Cancer Childhood Cancer
Survivors Study (CCSS) looked at the incidence of sec-
ondary malignancies in childhood cancer survivors treated
by radiotherapy between 1970 and 1986 [10]. The study
subjects were survivors of CNS tumors, Leukemia, HL, non-
HL, kidney tumors, neuroblastoma, soft tissue sarcomas,
and bone tumors. They found that the risk of subse-
quent cancer using multivariate analysis was increased in
females, childhood cancer of younger age, patients with
an initial diagnosis of HL or a soft tissue sarcoma, and
in patients treated with an alkylating agent. The main
three secondary malignancies in this cohort were tumors
of bone (19.14%), breast (16.18%), and thyroid (11.34%)
[10].
In conclusion, we presented a case of thymic Hodgkin
lymphoma in a 9-year-old boy who developed multiple sec-
o n d a r ym a l i g n a n c i e so v e rac o u r s eo f1 4y e a r so ff o l l o w - u p .
Modiﬁcations in therapeutic agents and avoiding radiation
therapy may reduce the risks of such complications in the
future.
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